ERBB2 and breast carcinoma: LFM-A13 is first inhibitor of Bruton’s tyrosine kinase (BTK) which decreases tumour progression in the MMTV/Neu transgenic mouse model of HER2 positive breast cancer as effectively as paclitaxel and gemcitabine.6